🟢 Arcturus Therapeutics is trading 29% up today after CSL settlement returned KOSTAIVE rights

Arcturus Therapeutics is trading 28.87% up now at $10.58 after Canaccord maintained its Buy rating while reducing the price target to $20 from $21.

• Investors also appear encouraged by the CSL collaboration settlement, which returned global KOSTAIVE rights, provided $12 million in cash, and removed approximately $16 million in R&D liabilities.
• Pipeline progress and conference visibility added support.